<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731250</url>
  </required_header>
  <id_info>
    <org_study_id>111611</org_study_id>
    <nct_id>NCT00731250</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Oral, Single Dose SB-705498 in a Validated Intranasal Capsaicin Challenge Model in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to look at the affect of SB-705498 on rhinitis symptoms, as induced by
      capsaicin challenge
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2008</start_date>
  <completion_date type="Actual">March 31, 2009</completion_date>
  <primary_completion_date type="Actual">March 1, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom scores and secretion weights</measure>
    <time_frame>up to 83 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak nasal inspiratory flow changes after challenge</measure>
    <time_frame>up to 83 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers levels in the nasal samples</measure>
    <time_frame>up to 83 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of drug</measure>
    <time_frame>up to 83 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response</measure>
    <time_frame>up to 83 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>up to 83 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>PART 1-Visit 1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive matching placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 1-Visit 1-Capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive incremental capsaicin doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 1-Visit 2-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive matching placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 1-Visit 2-Capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive maximum capsaicin dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 1-Visit 3-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive matching placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 1-Visit 3-Capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive matching placebo tablets incremental capsaicin doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 2-Visit 1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will receive matching placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 2-Visit 1-SB-705498</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive SB-705498 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PART 2-Visit 2-Capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive matching placebo tablets incremental capsaicin doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-705498</intervention_name>
    <description>Subjects will be administered a single dose of 400 mg SB-705498</description>
    <arm_group_label>PART 2-Visit 1-SB-705498</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be administered SB-705498 matching placebo tablets</description>
    <arm_group_label>PART 2-Visit 1-Placebo</arm_group_label>
    <arm_group_label>PART 1-Visit 3-Placebo</arm_group_label>
    <arm_group_label>PART 1-Visit 1-Placebo</arm_group_label>
    <arm_group_label>PART 1-Visit 2-Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Caspaicin</intervention_name>
    <description>Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose</description>
    <arm_group_label>PART 1-Visit 3-Capsaicin</arm_group_label>
    <arm_group_label>PART 2-Visit 2-Capsaicin</arm_group_label>
    <arm_group_label>PART 1-Visit 2-Capsaicin</arm_group_label>
    <arm_group_label>PART 1-Visit 1-Capsaicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy.

          -  Male or female between 18 and 60 years of age inclusive.

          -  Non-child bearing women or women of child bearing potential if they agree to use
             contraception as indicated by the protocol

          -  Non-smoker for at least 6 months with a pack history &lt;5 pack years (Pack years = (No.
             of cigarettes smoked/day/20) x No. of years smoked).

          -  Body weight &gt; 50 kg and body mass index (BMI) within the range 19 - 29.9 kg/m2
             (inclusive).

          -  Capable of giving written informed consent.

          -  Available to complete all the required study measurements.

          -  Normal 12-lead ECG at screening.

          -  For Part 2 only: The subject must demonstrate reactivity to unilateral, intranasal
             challenge with the selected single dose of capsaicin, defined as development of TSS ≥
             3.

        Exclusion Criteria:

          -  Past medical history of rhinitis, including allergic, non-allergic rhinitis and
             rhinosinusitis.

          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal
             perforation, nasal polyps, other nasal malformations.

          -  A history of gastrointestinal, hepatic, renal or multiple cardiovascular risk factors.

          -  Positive pre-study drug/alcohol screen.

          -  Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result
             within 3 months of screening.

          -  A positive test for human immunodeficiency virus (HIV) antibody (if determined by the
             local standard operating procedures (SOPs)).

          -  History of regular alcohol consumption within 6 months of the study.

          -  Exposure to more than four new chemical entities within 12 months prior to the start
             of the study.

          -  Participation in a clinical trial with a new molecule entity or any other clinical
             trial within 4 months of the start of the study.

          -  Use of prescription or non-prescription drugs, as well as of vitamins, herbal and
             dietary supplements (including St John's Wort) within 2 days prior to each study visit
             in Part 1 of the study or 14 days prior to the first treatment administration in Part
             2 of the study.

          -  Inability to abstain from all intranasal or oral medication to treat nasal symptoms
             from the first capsaicin challenge to the completion of the study including: sodium
             cromoglycate, antihistamines, anticholinergics, alpha-adrenergic agonists and
             corticosteroids

          -  History of drug or other allergy that, in the opinion of the Investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Subjects demonstrating hypersensitivity to the placebo capsaicin challenge at baseline
             screening.

          -  Donation of blood or blood products in excess of 500mL within a 56 day period prior
             the start of Part 2 of this study.

          -  Pregnant females as determined by positive serum or urine human chorionic gonadotropin
             (hCG) test at screening or prior to dosing.

          -  Lactating females.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Nicotine levels indicative of smoking or history or regular use of tobacco- or
             nicotine-containing products within 6 months prior to screening.

          -  For Part 2 only: Subjects with known lactose intolerance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/111611?search=study&amp;search_terms=111611#rs</url>
    <description>Results for study 111611 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capsaicin challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111611</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

